Literature DB >> 19327241

A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab.

C E Papagoras1, M I Argyropoulou, P V Voulgari, I Vrabie, A K Zikou, A A Drosos.   

Abstract

A 69-year-old woman with psoriatic arthritis treated with infliximab presented with low back pain of recent onset and fever. Serological, microbiological and imaging studies revealed Brucella spondylitis at the L5-S1 level. Immunosuppressive therapy was suspended and antibiotic therapy including doxycycline and rifampicin was administered for six months. The patient responded adequately with clinical and laboratory improvement and a considerable remission of spondylitis on repeat magnetic resonance imaging scan. The pathophysiology of tumor necrosis factor (TNF) alpha in Brucellosis and the role of anti-TNFalpha therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327241

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  3 in total

1.  When brucellosis met the Assessment of SpondyloArthritis international Society classification criteria for spondyloarthritis: a comparative study.

Authors:  Yiwen Wang; Dai Gao; Xiaojian Ji; Jie Zhang; Xiuru Wang; Jingyu Jin; Zheng Zhao; Xiaohu Deng; Chunhua Yang; Jian Zhu; Jianglin Zhang; Feng Huang
Journal:  Clin Rheumatol       Date:  2019-02-26       Impact factor: 2.980

2.  Subclinical sacroiliitis in brucellosis. Clinical presentation and MRI findings.

Authors:  T A Gheita; S Sayed; G S Azkalany; H S El Fishawy; M A Aboul-Ezz; M H Shaaban; R H Bassyouni
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

Review 3.  Side effects of TNF-α blockers in patients with psoriatic arthritis: evidences from literature studies.

Authors:  Rosario Peluso; Giovanni Cafaro; Alessandro Di Minno; Salvatore Iervolino; Pasquale Ambrosino; Gelsy Lupoli; Matteo Nicola Dario Di Minno
Journal:  Clin Rheumatol       Date:  2013-04-16       Impact factor: 3.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.